Katja Weisel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CHICAGO — Belantamab mafodotin monotherapy did not significantly extend PFS compared with the combination of pomalidomide and dexamethasone among adults with relapsed or refractory multiple myeloma, phase 3 study results showed. However, data from the randomized trial presented at ASCO Annual Meeting suggest that single-agent treatment with belantamab mafodotin (Blenrep, GSK) may have

/PRNewswire/ -- The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia,...

World Cancer Day is on February 4 and is commemorated in over 116 countries globally.

Credit: Dana-Farber Cancer Institute In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found. In a study posted online today by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer. These rates, and the duration of the responses...